ReviewJournal of clinical immunology2000
Gene therapy for autoimmune disorders.
Review in Journal of clinical immunology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 28 citations in OpenAlex.
- Gene Therapy for Cartilage Repair.Cartilage · 2011Review
- Clinical potential and challenges of using genetically modified cells for articular cartilage repair.Croatian medical journal · 2011Review
- [Molecular tools to remodel osteoarthritic articular cartilage : growth, transcription, and signaling factors].Der Orthopade · 2009Article
- B cells in autoimmunity.Arthritis research & therapy · 2009Review
- Gene transfer to human joints: progress toward a gene therapy of arthritis.Proceedings of the National Academy of Sciences of the United States of America · 2005Article
- Protective effects of IL-1Ra or vIL-10 gene transfer on a murine model of wear debris-induced osteolysis.Gene therapy · 2004Article
- Gene therapy in nonhuman primate models of human autoimmune disease.Gene therapy · 2003Review
- Endogenous regulation of a therapeutic transgene restores homeostasis in arthritic joints.The Journal of clinical investigation · 2002Article
- Future of adenoviruses in the gene therapy of arthritis.Arthritis research · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although many autoimmune disorders do not have a strong genetic basis, their treatment may nevertheless be improved by gene therapies. Most strategies seek to transfer genes encoding immunomodulatory products that will alter host immune responses in a beneficial manner. Used in this fashion, genes serve as biological delivery vehicles for the products they encode. By this means gene therapy overcomes obstacles to the targeted delivery of proteins and RNA, and improves their efficacy while providing a longer duration of effect, and, potentially, greater safety. Additional genetic strategies include DNA vaccination and the ablation of selected tissues and cell populations. There is considerable evidence from animal studies that gene therapies work: examples include the treatment of experimental models of rheumatoid arthritis, multiple sclerosis, diabetes, and lupus. Pre-clinical success in treating animal models of rheumatoid arthritis has led to the first clinical trial of gene therapy for an autoimmune disease. In this Phase I study, a cDNA encoding the interleukin-1 receptor antagonist was transferred to the knuckle joints of patients with advanced rheumatoid arthritis. Two additional clinical trials are in progress. It is likely that gene therapy will provide effective new treatments for a wide range of autoimmune disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.